Telix Pharmaceuticals agreed to acquire ITM Isotope Technologies Munich after the radiopharma peer was hit by a surprise FDA rejection, according to the reported deal terms. The transaction values the acquisition at at least $1.65 billion, with an additional $700 million potentially payable to ITM shareholders tied to regulatory and commercial milestones. The merger is positioned as a scale play in a market increasingly led by radioligand therapies that deliver radioisotopes directly to tumors. With Novartis already established via its earlier radiopharma launches, Telix’s larger platform could strengthen pipeline execution and manufacturing capacity. For the biotech sector, the headline is less about product readouts and more about consolidation—companies are combining capabilities to improve odds of navigating regulatory hurdles while expanding production footprint.